A Cost Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial

The AMBUVASC trial evaluated the cost effectiveness of outpatient vs. inpatient hospitalisation for endovascular repair lower extremity arterial disease (LEAD). was a national multicentre, prospective, randomised controlled conducted in nine public and two private French centres. primary endpoint incremental ratio (ICER), defined by per quality adjusted life year (QALY). Analysis from societal perspective, excluding indirect costs, considering one month time horizon. From 16 February 2016 to 29 May 2017, 160 patients were (80 group). A modified intention treat analysis performed with 153 (outpatient hospitalisation: n = 76; 77). mainly presented intermittent claudication arm: 97%; 92%). Rates peri-operative complications 20% (15 events) 18% (14 arms respectively (p .81). Overall costs (difference: €187.83; 95% confidence interval [CI] −275.68–651.34) QALYs 0.00277; CI –0.00237 – 0.00791) higher outpatients due more re-admissions than arm. mean ICER €67 741 QALY gained base case missing data imputed using multiple imputation predictive matching. procedure not effective willingness pay €50 000 probability being only 59% €100 000/QALY threshold. Outpatient is compared at